United Therapeutics Corp

UTHR · Health care (pharmaceutical preparations) · 10 years of annual accounts filed with the SEC · latest fiscal year ended 2025-12-31

Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›

United Therapeutics Corp reported revenue of $3.2 billion in fiscal 2025, after growing 7.9% a year over the previous 9 years. Its operating margin narrowed from 66.4% in 2016 to 46.9%. Of the $7.7 billion its operations generated over 10 years, 35.7% went to buybacks and 22.2% back into the business; the share count rose 2.4%. On the accounting screens, it passes 7 of 8 Piotroski tests, its Altman Z'' of 16.93 is in the safe zone and its Beneish M-score is below the -1.78 line; none of the six cross-checks between its statements fires.

Revenue, fiscal 2025 3.2B +7.9% a year over 9 years

Operating margin 46.9% gross margin 87.9%

Return on invested capital —

Free cash flow after stock pay 893.0M 28.1% of revenue

Net debt ÷ EBITDA — net debt —

Piotroski F-score 7/8 tests of improvement passed

Is it growing?

Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.

RevenueOperating income

Compound growth a year
	3 yrs	5 yrs	9 yrs
Revenue	+18.0%	+16.5%	+7.9%
Operating income	+15.1%	+20.2%	+3.9%
Net income	+22.4%	—	+7.2%
Earnings per share	+22.9%	—	+6.9%
Free cash flow per share	+16.7%	+6.8%	+5.9%
Shares	-0.4%	+1.4%	+0.3%

Falling shares are buybacks: each remaining share owns more of the company.

Does it earn more than its capital costs?

Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.

    GrossOperatingNetFree cash flow
    
  

Return on invested capital

Return on invested capital Cost of capital today · 10.2%

Economic profit

Needs a cost of capital, which comes from the valuation below.

Return on equity: 18.8%
Return on assets: 16.9%
Asset turnover: 0.40×
Research & development: 17.3% of revenue
Overheads (SG&A): 23.7% of revenue

Is the profit cash, and where does the cash go?

Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.

Net incomeFree cash flowAfter stock-based pay

Where 10 years of operating cash went, 2016–2025

7.7B generated by the business. Each band is its share of that total.

Reinvested in the business 22% 1.7B
Acquisitions 3% 218.5M
Dividends 0% 0
Share buybacks 36% 2.8B
Kept, or used to pay down debt 39% 3.0B

Over the same years it paid 844.5M in stock. The share count rose 2.4%. 1.9B of the buybacks went beyond offsetting that dilution.

Per share

    Earnings per shareFree cash flow per shareDividend per share
    
  

Shares outstanding

Diluted shares

Debt and liquidity

Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.

Net debt ÷ EBITDA: —
Interest coverage: 77× operating income ÷ interest
Current ratio: 6.60 current assets ÷ current liabilities
Cash conversion cycle: 207 days collects in 40d, stock 174d, pays in 7d

Three classic screens of the accounts

Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.

Piotroski F-score

Is the business improving? Nine yes-or-no tests, this year against last.

7of 8 tests passed

ProfitableReturn on assets above zero passed
Cash from operationsOperating cash flow above zero passed
Profitability improvedReturn on assets higher than a year before passed
Profit backed by cashOperating cash flow above net income (low accruals) passed
Less long-term debtLong-term debt as a share of assets fell — not reported no data
More liquidCurrent ratio higher than a year before passed
No new sharesShare count did not grow passed
Better gross marginGross margin higher than a year before failed
Sells more per assetAsset turnover higher than a year before passed

Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.

Altman Z''-score

Does the balance sheet look like those of companies that went bankrupt?

16.93safe zone

Working capital ÷ assets 0.40 × 6.56+2.62
Retained earnings ÷ assets 1.09 × 3.26+3.54
Operating income ÷ assets 0.19 × 6.72+1.27
Equity ÷ liabilities 9.05 × 1.05+9.51

Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.

Beneish M-score

Do the accounts resemble those of companies that manipulated their earnings?

-2.26below the -1.78 line

Receivables vs sales 1.13+1.04
Gross margin slipping 1.01+0.54
Soft assets 1.01+0.41
Sales growth 1.11+0.99
Slower depreciation 1.19+0.14
Overheads vs sales 0.96-0.17
Profit not in cash -0.03-0.13
Leverage rising 0.71-0.23

Where it misleads: fast growth and acquisitions. Sales growth carries a heavy weight, so a company growing 50% a year scores like a suspect without having done anything. It is a screen from a 1999 study, not an accusation.

Where the statements disagree

Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.

None of the six cross-checks fires for the latest year: receivables and inventory move with revenue, profit turns into cash, investment keeps up with depreciation, the tax rate is ordinary and debt is moderate.

What is it worth, under which assumptions?

A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.

Revenue

Starting revenue

M $

revenue of fiscal 2025

Growth in year one

revenue grew +16.5% a year over the last 5 years; it fades to the terminal rate by the last year

Years until it settles

yrs

ten years for growth to fade to the terminal rate

Cash from each sale

Free cash flow margin today

free cash flow to the firm after stock-based pay ÷ revenue, last 3 fiscal years together

Margin in the last year

the margin in year ten; by default the business keeps today's

Count stock-based pay as a costIt is paid in shares instead of cash, and shareholders bear it through dilution. Most free cash flow figures leave it out.

The long run

Growth after that, forever

growth forever after year ten, below the risk-free rate: no company outgrows the economy forever

The discount rate

Risk-free rate

10-year US Treasury par yield (U.S. Treasury), 2026-09-28

Beta

not measured on this public page, which uses only public filings: 1.0 assumes it moves like the market. Sign in to measure it from prices

Equity risk premium

the extra return demanded for holding shares; it cannot be measured, and 4–6% is the common range

Cost of debt, before tax

no interest line: the risk-free rate + 1.5 points

Tax rate

effective rate in the last fiscal year, 22.1%, kept within 0–35%

The price

Share price

Type the price you see at your broker. It is used only for the reverse questions: what that price implies.

Back to the defaults

SEC from the filings Treasury the 10-year yield measured from prices assumption cannot be measured yours you changed it

Value per share, with these assumptions $333.32 discounted at 10.2% a year · 53% of it from after year 10

$253.5780% of 5,000 simulations$450.20

Cautious $213.36 12.5% growth · 18.5% margin · 11.2% discount · 2.0% forever

Your assumptions $333.32 16.5% growth · 21.7% margin · 10.2% discount · 2.5% forever

Generous $543.57 20.5% growth · 25.0% margin · 9.2% discount · 3.0% forever

Type a share price on the left to ask the reverse questions: what growth, what margin or what discount rate that price implies.

What the value implies, in the usual multiples

	At this model's value
Price ÷ earnings	12.0×
Enterprise value ÷ EBITDA	10.1×
Enterprise value ÷ revenue	5.0×
Free cash flow yield	5.6%

From cash flows to a value per share

10 years of cash flow, today7.5B

Everything after, today8.5B

The whole business16.0B

Minus net debt-0

What belongs to shareholders16.0B

Divided among 47.9M shares: $333.32 each.

The projection next to its history

Reported free cash flow after stock pay, then the model's. A projection that looks nothing like the past needs a reason.

ReportedProjected

Year by year

	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Revenue	3.7B	4.3B	4.8B	5.4B	6.0B	6.5B	6.9B	7.3B	7.6B	7.8B
Growth	16.5%	14.9%	13.4%	11.8%	10.3%	8.7%	7.2%	5.6%	4.1%	2.5%
Cash margin	21.7%	21.7%	21.7%	21.7%	21.7%	21.7%	21.7%	21.7%	21.7%	21.7%
Free cash flow	805.7M	926.1M	1.1B	1.2B	1.3B	1.4B	1.5B	1.6B	1.7B	1.7B
Worth today	730.8M	762.0M	783.8M	795.1M	795.4M	784.4M	762.6M	730.5M	689.6M	641.1M

If the least-known inputs move

Value per share as two inputs change at a time. Neighbouring cells that differ a lot are the conclusion: the value depends on numbers nobody knows to a point.

The discount rate and growth forever

discount ↓ · forever →	1.5%	2.0%	2.5%	3.0%	3.5%
9.2%	345	364	387	413	444
9.7%	322	339	358	380	406
10.2%	302	317	333	352	374
10.7%	284	297	311	328	346
11.2%	268	279	292	306	322

Year-one growth and the final margin

margin ↓ · growth →	12.5%	14.5%	16.5%	18.5%	20.5%
17.4%	241	260	281	303	327
19.6%	263	284	307	332	358
21.7%	285	308	333	360	389
23.9%	307	332	359	388	420
26.1%	329	356	386	417	450

All the inputs moving at once

5,000 valuations, each with growth, final margin, discount rate and growth forever drawn at random around the values on the left (spreads of 3.0%, 3.3%, 1.0% and 0.5%). Not a probability — the spreads are assumptions too — but an honest picture of how wide the answer is.

10th percentile$253.57

Median$333.83

90th percentile$450.20

Half of the simulations land between $287.74 and $387.72; one in ten below $253.57, one in ten above $450.20.

Does the long run make sense?

5.8×The terminal value prices the business in year 10 at 5.8 times that year's EBITDA.
6%To grow 2.5% forever while reinvesting 41% of its after-tax operating profit, the business must earn 6% on the new capital.
53%of the value comes from after year 10. The more of it, the more the answer depends on the part nobody can see.

The discount rate, taken apart

What shareholders demand (CAPM): 5.24% risk-free + 1.00 beta × 5.0% premium = 10.24%.
What lenders charge, after the tax saving on interest: 6.74% × (1 − 22.1%) = 5.25%.
Weighted by how much of each the company uses (book value (no price given)): 10.24%, the rate every future cash flow is discounted at.

What it has filed lately

The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.

Event 2026-09-08

Signed a material agreement; published information for investors

Changed a director or officer; published information for investors

Event 2026-06-29

Changed a director or officer; published the results of a shareholder vote

Published other information

Estimatein 34d

Results for the period ending 2026-09-29

What its own directors and officers did

Every Form 4 filed in the last twelve months, read line by line: 6 filings by 2 people. Open-market purchases and sales are counted apart from awards, option exercises and shares withheld for taxes.

Bought on the open market—none in the period

Sold on the open market$27.4M51 sale(s) by 2 insider(s)

Under pre-arranged plans100%of the sales followed a 10b5-1 plan set months earlier

Other lines60 awards · 6 option exercises · 0 tax withholdings

Date	Who	What	Shares	Price	Value	Holds after
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Exercised options · indirect	9,500	$117.76	$1.1M	333,943
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	640	$469.74	$300,631	333,303
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	2,603	$470.63	$1.2M	330,700
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	2,160	$471.77	$1.0M	328,540
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	580	$472.73	$274,184	327,960
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	437	$474.01	$207,141	327,523
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	320	$475.35	$152,114	327,203
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	280	$476.51	$133,424	326,923
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	360	$477.58	$171,930	326,563
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	1,480	$478.61	$708,337	325,083
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	600	$479.52	$287,710	324,483
24 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	40	$480.33	$19,213	324,443
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Exercised options · indirect	9,500	$117.76	$1.1M	333,943
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	2,388	$488.70	$1.2M	331,555
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	2,162	$489.52	$1.1M	329,393
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	1,440	$490.48	$706,286	327,953
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	824	$491.65	$405,124	327,129
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	480	$492.54	$236,421	326,649
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	160	$493.72	$78,996	326,489
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	155	$495.17	$76,752	326,334
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	525	$496.38	$260,598	325,809
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	766	$497.27	$380,908	325,043
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	270	$498.38	$134,563	324,773
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	90	$498.90	$44,901	324,683
23 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	240	$500.05	$120,012	324,443
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Exercised options · indirect	9,500	$117.76	$1.1M	333,943
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	240	$489.61	$117,507	333,703
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	424	$490.54	$207,988	333,279
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	736	$491.45	$361,705	332,543
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	628	$492.67	$309,395	331,915
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	1,645	$493.70	$812,139	330,270
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	1,337	$494.66	$661,358	328,933
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	1,488	$495.77	$737,700	327,445
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	1,484	$496.83	$737,295	325,961
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	1,358	$497.73	$675,912	324,603
22 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	160	$499.07	$79,851	324,443
21 Sep 2026	Rothblatt Martine AChairperson & CEO	Exercised options · indirect	9,500	$117.76	$1.1M	333,943
21 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	1,520	$492.97	$749,321	332,423
21 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	2,680	$493.60	$1.3M	329,743
21 Sep 2026	Rothblatt Martine AChairperson & CEO	Sold on the open market · pre-arranged plan · indirect	2,170	$494.82	$1.1M	327,573

The 40 most recent lines of 57.

A Form 4 says what happened, when, how many shares and at what price. It does not say why: a sale can be diversification, a tax bill or a plan fixed months earlier, and an award is pay, not a purchase. Nothing here is a reason to buy or sell anything.

Which large funds report holding it

From the Form 13F of the 28 institutions followed on this site, as of the end of their last reported quarter. A 13F is filed up to 45 days later and shows only long positions in US-listed shares.

Fund	Shares	Value	Share of the fund	Since the quarter before
Norges Bank (Norway's sovereign fund) 30 Jun 2026	694,753	$376.4M	0.0%	New
Baillie Gifford 30 Jun 2026	467,209	$253.1M	0.2%	Added to
Bridgewater Associates 30 Jun 2026	111,326	$60.3M	0.2%	Unchanged
Tudor Investment 30 Jun 2026	12,667	$6.9M	0.0%	New

All the funds and what they reported ›

Companies like this one

Same SEC industry (pharmaceutical preparations) first, then the rest of health care.

LLY ELI Lilly & Co JNJ Johnson & Johnson ABBV AbbVie Inc.MRK Merck & Co., Inc.ABT Abbott Laboratories PFE Pfizer Inc VRTX Vertex Pharmaceuticals Inc / MA BMY Bristol Myers Squibb Co

Every figure, year by year

10 fiscal years · 30 measures

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Size
Revenue	1.6B	1.7B	1.6B	1.4B	1.5B	1.7B	1.9B	2.3B	2.9B	3.2B
Revenue growth	—	+7.9%	-5.7%	-11.0%	+2.4%	+13.6%	+14.9%	+20.2%	+23.6%	+10.6%
Operating income	1.1B	814.9M	805.4M	-187.6M	593.6M	555.9M	979.7M	1.2B	1.4B	1.5B
Net income	713.7M	417.9M	589.2M	-104.5M	—	475.8M	727.3M	984.8M	1.2B	1.3B
Margins
Gross margin	95.5%	93.9%	87.8%	91.9%	92.7%	92.7%	92.2%	88.9%	89.2%	87.9%
Operating margin	66.4%	47.2%	49.5%	-12.9%	40.0%	33.0%	50.6%	50.9%	47.9%	46.9%
Net margin	44.6%	24.2%	36.2%	-7.2%	—	28.2%	37.6%	42.3%	41.5%	41.9%
Free cash flow margin	37.9%	22.5%	36.5%	-20.0%	46.9%	28.3%	34.3%	32.1%	37.6%	32.7%
R&D ÷ revenue	9.2%	15.3%	22.0%	81.6%	24.1%	32.0%	16.7%	17.5%	16.7%	17.3%
SG&A ÷ revenue	19.8%	19.1%	16.3%	—	—	27.7%	24.9%	20.5%	24.7%	23.7%
Cash
Free cash flow	605.6M	387.9M	594.0M	-290.3M	696.4M	477.4M	663.7M	747.6M	1.1B	1.0B
Stock-based pay	12.1M	73.5M	-26.4M	45.4M	163.8M	138.5M	106.8M	39.1M	144.0M	147.7M
Free cash flow after stock pay	593.5M	314.4M	620.4M	-335.7M	532.6M	338.9M	556.9M	708.5M	936.6M	893.0M
Free cash flow to the firm	708.3M	297.1M	619.8M	-275.5M	464.0M	325.6M	632.5M	671.7M	849.2M	632.4M
Free cash flow ÷ net income	0.8×	0.9×	1.0×	2.8×	—	1.0×	0.9×	0.8×	0.9×	0.8×
Capex ÷ revenue	2.4%	5.0%	11.3%	5.8%	4.0%	7.2%	7.2%	9.9%	8.6%	16.4%
Returns
Return on invested capital	—	—	—	—	—	—	—	—	—	—
Return on equity	38.6%	19.9%	21.1%	-3.8%	—	12.0%	15.2%	16.5%	18.5%	18.8%
Return on assets	30.7%	14.5%	17.3%	-2.7%	—	9.2%	12.0%	13.7%	16.2%	16.9%
Asset turnover	0.7×	0.6×	0.5×	0.4×	0.3×	0.3×	0.3×	0.3×	0.4×	0.4×
Economic profit	—	—	—	—	—	—	—	—	—	—
Per share
Earnings per share	$15.25	$9.31	$13.39	$-2.39	—	$10.06	$15.00	$19.81	$24.64	$27.86
Free cash flow per share	$12.94	$8.64	$13.50	$-6.63	$15.61	$10.09	$13.68	$15.04	$22.28	$21.73
Dividend per share	—	—	—	—	—	—	—	—	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—
Book value per share	$43.09	$48.61	$63.98	$63.36	$76.28	$87.77	$104.20	$127.23	$143.74	$162.60
Diluted shares	46.8M	44.9M	44.0M	43.8M	44.6M	47.3M	48.5M	49.7M	48.5M	47.9M
Balance sheet
Net debt	—	—	—	—	—	—	—	—	—	—
Net debt ÷ EBITDA	—	—	—	—	—	—	—	—	—	—
Interest coverage	272.2×	90.5×	57.9×	-4.2×	25.3×	29.9×	30.2×	20.0×	32.1×	76.5×
Current ratio	4.3×	3.3×	6.4×	4.0×	6.7×	7.6×	9.8×	4.4×	5.2×	6.6×
Cash conversion cycle (days)	510	406	182	297	317	311	277	194	214	207
Scores
Piotroski F-score	—	4	6	2	3	6	5	4	8	7
Altman Z''	13.76	10.32	12.70	7.37	9.12	9.44	11.14	11.68	14.60	16.93
Beneish M	—	-1.94	-2.95	-2.59	—	-2.28	-2.50	-2.42	-2.60	-2.26

Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.